• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.

作者信息

Sabatine Marc S, Giugliano Robert P, Schwartz Gregory G

机构信息

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Cardiology Section, Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, CO, USA.

出版信息

Expert Rev Clin Pharmacol. 2021 Feb;14(2):281-282. doi: 10.1080/17512433.2021.1874346. Epub 2021 Jan 12.

DOI:10.1080/17512433.2021.1874346
PMID:33428482
Abstract
摘要

相似文献

1
Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.致编辑的信：关于“ClinicalTrials.gov上报告的PCSK9抑制剂试验中的严重不良事件和死亡：一项系统评价”
Expert Rev Clin Pharmacol. 2021 Feb;14(2):281-282. doi: 10.1080/17512433.2021.1874346. Epub 2021 Jan 12.
2
Response to letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.对致编辑信的回复：关于“ClinicalTrials.gov上报告的PCSK9抑制剂试验中的严重不良事件和死亡：一项系统评价”
Expert Rev Clin Pharmacol. 2021 Feb;14(2):283-284. doi: 10.1080/17512433.2021.1874350. Epub 2021 Jan 19.
3
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.ClinicalTrials.gov 上报告的 PCSK9 抑制剂试验中的严重不良事件和死亡：系统评价。
Expert Rev Clin Pharmacol. 2020 Jul;13(7):787-796. doi: 10.1080/17512433.2020.1787832. Epub 2020 Jul 13.
4
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.不同降脂策略后低密度脂蛋白胆固醇、游离前蛋白转化酶枯草溶菌素/克新9型与阿利西尤单抗水平之间的关系
J Am Heart Assoc. 2016 Jun 10;5(6):e003323. doi: 10.1161/JAHA.116.003323.
5
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.PCSK9 抑制剂依洛尤单抗降低 LDL-胆固醇水平的临床疗效和安全性：FOURIER 试验的预先设定的次要分析。
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
6
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.用于治疗高胆固醇血症的前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：对中风风险的影响。
Eur J Intern Med. 2016 Oct;34:54-57. doi: 10.1016/j.ejim.2016.06.023. Epub 2016 Jun 28.
7
Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.
Med Lett Drugs Ther. 2015 Oct 12;57(1479):140-1.
8
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.前蛋白转化酶枯草溶菌素9（PCSK9）单克隆抗体依洛尤单抗和阿利西尤单抗的治疗潜力及批判性分析
Ann Pharmacother. 2015 Dec;49(12):1327-35. doi: 10.1177/1060028015608487. Epub 2015 Sep 30.
9
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.依洛尤单抗联合常规药物治疗，伴或不伴血浆分离术，用于治疗纯合子家族性高胆固醇血症患者：开放标签 TAUSSIG 研究的中期亚组分析。
Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16.
10
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.

引用本文的文献

1
Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study.依洛尤单抗和阿利西尤单抗试验中基线失衡的定量评估：一项荟萃流行病学研究。
BMC Med Res Methodol. 2024 Jun 22;24(1):137. doi: 10.1186/s12874-024-02260-z.